Re: New Data

ReNeuron Group plc
31 May 2007

ReNeuron announces new data concerning its ReNcell(R) neural stem cell lines



Guildford, UK, 31 May 2007: ReNeuron Group plc (LSE: RENE.L) today announces new
data concerning its ReNcell(R)CX and ReNcell(R)VM neural cell lines.  These cell
lines are marketed through Millipore Corporation as drug discovery tools for
academic and commercial research.



The data were generated in collaboration with Drs Roberta Donato and Frances
Edwards at the Department of Physiology, University College London (UCL).  The
results demonstrate that the ReNcell(R)CX and ReNcell(R)VM lines can be
continuously expanded in monolayer culture and will differentiate into the three
principal neural cell types: neurons, astrocytes and oligodendrocytes.  In the
case of the ReNcell(R)VM line, a renewable source of stable, functional and
electrophysiologically active dopaminergic neurons was demonstrated.



The results are published in the on-line journal, BMC Neuroscience

(http://www.biomedcentral.com/1471-2202/8/36/abstract)



Dr John Sinden, Chief Scientific Officer of ReNeuron, said:



'We are pleased to have further validated the utility of our first generation
ReNcell neural cell lines through this collaboration with UCL. The ability of
the ReNcell(R) lines to functionally differentiate in vitro makes them
potentially powerful research tools in the discovery of new therapies targeting
diseases of the central nervous system, including Parkinson's  Alzheimer's and
Huntington's diseases as well as schizophrenia and depression.'



Enquiries:


ReNeuron
Michael Hunt, Chief Executive Officer                    Tel: [phone]
Dr John Sinden, Chief Scientific Officer


Financial Dynamics
David Yates                                             Tel: [phone]
Nicola Daley





Notes to Editors



ReNeuron is a leading, UK-based stem cell therapy business.  It is applying its
novel stem cell platform technologies in the development of ground-breaking stem
cell therapies to serve significant and unmet or poorly-met clinical needs.



ReNeuron has used its c-mycER technology to generate genetically stable neural
stem cell lines.  This technology platform has multi-national patent protection
and is fully regulated by means of a chemically-induced safety switch.  Cell
growth can therefore be completely arrested prior to in vivo implantation.



ReNeuron has filed for approval to commence initial clinical studies in the US
with its lead ReN001 stem cell therapy for chronic stroke disability.  This
represents the world's first such filing concerning a neural stem cell treatment
for a major neurological disorder.  ReNeuron has also generated pre-clinical
efficacy data with its ReN005 stem cell therapy for Huntington's disease, a
genetic and fatal neurodegenerative disorder that affects around 1 in 10,000
people.  This programme is in pre-clinical development.  In addition to its
stroke and Huntington's disease programmes, ReNeuron is developing stem cell
therapies for Parkinson's disease, Type 1 diabetes and diseases of the retina.



ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell(R) range of cell lines for use in research and in drug
discovery applications in the pharmaceutical industry.  ReNeuron's ReNcell(R)CX
and ReNcell(R)VM neural cell lines are marketed worldwide under license by
Millipore Corporation.



ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.



Further information on ReNeuron and its products can be found at
www.reneuron.com.



Data sources: UK Stroke Association; American Stroke Association.



This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.



The terms 'ReNeuron', 'the Company' or 'the Group' used in this statement refer
to ReNeuron Group plc and/or its subsidiary undertakings, depending on the
context.




                      This information is provided by RNS
            The company news service from the London Stock Exchange